From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas

In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xueyuan, Turcan, Sevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157002/
https://www.ncbi.nlm.nih.gov/pubmed/34067729
http://dx.doi.org/10.3390/cells10051225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157002/
https://www.ncbi.nlm.nih.gov/pubmed/34067729
http://dx.doi.org/10.3390/cells10051225

Ejemplares similares